

Exhibit 1001

U.S. Patent No. 7,332,183 (“the ‘183 Patent”)



US007332183B2

(12) **United States Patent**
Plachetka et al.

(10) **Patent No.:** **US 7,332,183 B2**
(45) **Date of Patent:** **Feb. 19, 2008**

(54) **MULTILAYER DOSAGE FORMS
CONTAINING NSAIDS AND TRIPTANS**

(75) Inventors: **John R. Plachetka**, Chapel Hill, NC
(US); **Venkata Markandeya
Kothapalli**, Cary, NC (US); **Donna L.
Gilbert**, Chapel Hill, NC (US)

(73) Assignee: **Pozen Inc.**, Chapel Hill, NC (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 650 days.

6,245,802	B1	6/2001	Iyengar et al.	514/438
6,365,184	B1	4/2002	Depui et al.	424/469
6,368,627	B1	4/2002	Phillips et al.	424/480
6,384,034	B2	5/2002	Simitchieva et al.	514/252
6,387,410	B1	5/2002	Woolfe et al.	424/489
6,635,281	B2*	10/2003	Wong et al.	424/473
6,797,283	B1*	9/2004	Edgren et al.	424/472
6,863,901	B2*	3/2005	Hirsh et al.	424/472
2002/0016348	A1	2/2002	Simitchieva et al.	
2002/0099059	A1	7/2002	Saper	514/263.31
2003/0203027	A1*	10/2003	Verreck et al.	424/471
2003/0232876	A1	12/2003	Plachetka	514/419
2007/0184109	A1*	8/2007	Floyd et al.	424/465

(21) Appl. No.: **10/741,592**

(22) Filed: **Dec. 22, 2003**

(65) **Prior Publication Data**

US 2004/0180089 A1 Sep. 16, 2004

Related U.S. Application Data

(60) Provisional application No. 60/436,000, filed on Dec.
26, 2002.

(51) **Int. Cl.**
A61K 9/24 (2006.01)

(52) **U.S. Cl.** **424/472**

(58) **Field of Classification Search** **424/472,**
424/473, 474

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

701,438	A*	6/1902	Whyte	424/464
2,951,792	A*	9/1960	Swintosky	424/472
3,048,526	A*	8/1962	Boswell	424/472
3,317,394	A*	5/1967	Ostholm et al.	424/472
3,358,687	A*	12/1967	Miley et al.	604/288
4,024,279	A	5/1977	Zor et al.	424/319
4,786,500	A*	11/1988	Wong	424/422
4,814,181	A*	3/1989	Jordan et al.	424/473
4,816,470	A	3/1989	Dowle et al.	514/415
4,946,685	A*	8/1990	Edgren et al.	424/472
5,307,845	A	5/1994	Vanrobaeys et al.	139/1 R
5,307,953	A	5/1994	Regan	222/82
5,360,925	A	11/1994	Chabrier de Lassauniere et al.	560/169
5,387,604	A	2/1995	McDonald et al.	514/456
5,425,950	A*	6/1995	Dandiker et al.	424/480
5,474,995	A	12/1995	Ducharme et al.	514/241
5,480,650	A	1/1996	Marchi et al.	424/464
5,514,168	A	5/1996	Friedman	607/89
5,554,639	A	9/1996	Craig et al.	514/415
5,605,917	A	2/1997	Ogletree	514/365
5,607,960	A	3/1997	Wythes	514/414
5,618,816	A	4/1997	Crenshaw et al.	514/253
5,637,320	A	6/1997	Bourke et al.	424/489
5,698,571	A	12/1997	Audia et al.	514/323
5,705,520	A	1/1998	Craig et al.	514/415
5,807,571	A	9/1998	List	424/449
5,872,145	A	2/1999	Plachetka	514/415
5,942,503	A	8/1999	Jung et al.	514/214
6,060,499	A	5/2000	Plachetka	514/415
6,077,520	A*	6/2000	Plachetka et al.	424/474

FOREIGN PATENT DOCUMENTS

CS	277 525	2/1993
DE	195 42 281	5/1997
EP	0 117 164	8/1984
EP	0 379 314	7/1990
EP	0 447 727	9/1991
EP	1 051 993 A2	11/2000
EP	1 051 995 A2	11/2000
EP	1 064 948 A2	1/2001
EP	1 064 966 A2	1/2001
EP	1 064 967 A2	1/2001
EP	1 126 841	12/2004
GB	2 124 210	2/1984
GB	2 135 884	9/1984
GB	2 162 522	2/1986
JP	8-208516	8/1996
WO	WO 94/26270	11/1994

(Continued)

OTHER PUBLICATIONS

Certified Translation of EP 0 117 164, Reference B9 above.

Andersson, et al., "Double-Blind Study of Naproxen vs Placebo in the Treatment of Acute Migraine Attacks," *Cephalalgia* 9:29-32 (1989).

Baumel, "Migraine: A Pharmacologic Review with Newer Options and Delivery Modalities," *Neurology* 44:S13-S17 (1994).

Bolten, "Scientific Rationale for Specific Inhibition of COX-2," *J. Rheumatol.* 25:2-7 (1998).

Boureau, et al., "Comparison of Subcutaneous Sumatriptan with Usual Acute Treatments for Migraine," *Eur. Neurol.* 35:264-269 (1995).

(Continued)

Primary Examiner—Sharon Kennedy
(74) *Attorney, Agent, or Firm*—Michael A. Sanzo; Law
Office of Michael A. Sanzo, LLC

(57) **ABSTRACT**

The present invention is directed to multilayer pharmaceutical tablets in which an NSAID and a triptan are present in separate and distinct layers. The layers are in a side-by-side configuration, which allows the dissolution of triptan and NSAID to occur independently and immediately.

20 Claims, 1 Drawing Sheet

FOREIGN PATENT DOCUMENTS

WO	WO 97/38986	10/1997
WO	WO 98/06392	2/1998
WO	WO 98/15275	4/1998
WO	WO 98/20870	5/1998
WO	WO 99/45905	9/1999
WO	WO 00/06161	2/2000
WO	WO 00/25779	5/2000
WO	WO 00/48583	8/2000

OTHER PUBLICATIONS


- Boussier, et al., "Combined Low-Dose Acetylsalicylic Acid and Dihydroergotamine in Migraine Prophylaxis," *Cephalalgia* 8:187-102 (1988).
- Boussier, et al., "Efficacy of Subcutaneous Sumatriptan in the Acute Treatment of Early-Morning Migraine: A Placebo-Controlled Trial," *J. Intern. Med.* 234:211-216 (1993).
- Cady, et al., "Treatment of Acute Migraine with Subcutaneous Sumatriptan," *JAMA* 265:2831-2835 (1991).
- Cady, et al., "Efficacy of Subcutaneous Sumatriptan in Repeated Episodes of Migraine," *Neurology* 43:1363-1368 (1993).
- Cady, et al., "Recent Advances in Migraine Management," *J. Family Practice* 36(1):85-91 (1993).
- Capobianco, et al., "An Overview of the Diagnosis and Pharmacologic Treatment of Migraine," *Mayo Clin. Proc.* 71:1055-1066 (1996).
- Centonze, et al., "Evaluation of the Efficacy of Oral Sumatriptan in the Management of Migraine Attacks. Clinical Results," *La Clinica Terapeutica* 146:721-728 (1995). (Article in Italian with English Abstract).
- Dahlöf, "How Does Sumatriptan Perform in Clinical Practice," *Cephalalgia* 15:21-28 (1995).
- Dechant, et al., "Sumatriptan—A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in the Acute Treatment of Migraine and Cluster Headache," *Drugs* 43:776-798 (1992).
- Demarin, et al., "Pharmacotherapy of Migraine," *Acta Clin. Croat.* 34:81-89 (1995).
- Donnelly, et al., "Review Article: COX-II Inhibitors—A New Generation of Safer NSAIDs?," *Aliment. Pharmacol. Ther.* 11:227-236 (1997).
- Furlong, et al., "Prescribing Practices for the Management of Headache in Newfoundland and Labrador," *Headache* 36:542-546 (1996).
- Furst, "Meloxicam: Selective COX-2 Inhibition in Clinical Practice," *Semin. Arthritis Rheum.* 26:21-27 (1997).
- Grazzi, et al., "A Review of the Treatment of Primary Headaches. Part I: Migraine," *Intl. J. Neurol. Sci.* 16:577-586 (1995).
- Griswold, et al., "Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date," *Med. Res. Rev.* 16:181-206 (1996).
- Haag, "Kombianalgetika in der Kopfschmerz-therapie," *Duetsche Apotheker Zeitung, De, Deutscher Apotheker Zeitung* 4:43-48 (1993) Stuttgart.
- Hoernecke, et al., "Treatment of Migraine Attacks: Combination of Dihydroergotamine Tartrate and Paracetamol in Comparison with Individual Drugs and Placebo," *Medizinische Klinik* 88:642-648 (1993); Abstract from Medline Online, Database Accession No. NLM8295604.
- Klapper, "The Pharmacologic Treatment of Acute Migraine Headaches," *J. Pain Symptom Manage.* 8:140-147 (1993).
- Klapper, "Toward a Standard Drug Formulary for the Treatment of Headache," *Headache* 35:225-227 (1995).
- Kumar, "Recent Advances in the Acute Management of Migraine and Cluster Headaches," *J. Gen. Internal Med.* 9:339-348 (1994).
- Krymchantowski, et al., "Tolfenamic Acid Decreases Migraine Recurrence When Used with Sumatriptan," *Cephalalgia* 19:186-187 (1999).
- Krymchantowski, et al., "Naproxen Sodium Decreases Migraine Recurrence When Used with Sumatriptan," *Cephalalgia* 19:357-358 (1999).
- Lance, "Headache," *Ann. Neurol.* 10:1-10 (1981).
- Lane, "Pain Management in Osteoarthritis: The Role of COX-2 Inhibitors," *J. Rheumatol.* 24:20-24 (1997).
- Lipsky, et al., "Outcome of Specific COX-2 Inhibition in Rheumatoid Arthritis," *J. Rheumatol.* 24:9-14 (1997).
- Mathew, "Cyclical Prophylactic Treatment of Menstrual Migraine Using Naproxen and Ergotamine," *Headache* 26:314 (1986).
- Mathew, et al., "Advances in Migraine Drug Therapy," *Drug Therapy* 23:37-48 (1993).
- Moskowitz, et al., "Neuroeffector Functions of Sensory Fibres: Implications for Headache Mechanisms and Drug Actions," *J. Neurol.* 238:S-18-S22 (1991).
- Myllylä, et al., "Tolfenamic Acid Rapid Release Versus Sumatriptan in the Acute Treatment of Migraine: Comparable Effect in a Double-Blind, Randomized, Controlled, Parallel-Group Study," *Headache* 38:201-207 (1998).
- Oral Sumatriptan Group, "Sumatriptan—An Oral Dose-Defining Study," *Eur. Neurol.* 31:300-305 (1991).
- Parma, et al., "Il Trattamento dell'Emicrania: Uno Studio Nella Medicina Generale," *Ricerca & Pratica* 11:64-72 (1995) in Italian.
- Translation of AK5 above: Parma, et al., "The Treatment of Migraine: A Study in General Medicine," *Ricerca & Pratica* 11:64-72 (1995).
- Peroutka, "Beyond Monotherapy: Rational Polytherapy in Migraine," *Headache* 38:18-22 (1998).
- Pfaffenrath, et al., "Efficacy and Safety of Sumatriptan Tablets (25 mg, 50 mg, and 100 mg) in the Acute Treatment of Migraine: Defining the Optimum Doses of Oral Sumatriptan," *Headache* 38:184-190 (1998).
- Plosker, et al., "Sumatriptan: A Reappraisal of Its Pharmacology and Therapeutic Efficacy in the Acute Treatment of Migraine and Cluster Headache," *Drugs* 47:622-651 (1994).
- Pradalier, et al., "La Migraine Cataméniale," *Contracept. Fertil. Sex.* 23:361-365 (1995) in French.
- Translation of AP5 above: Pradalier, et al., "Menstrual Migraine," *Contracept. Fertil. Sex.* 23:361-365 (1995).
- Prusinski, "Monotherapy or Polytherapy in Migraine," *Neuroepidemiology* 6:186-189 (1987).
- Rac, et al., "Formulation of Antimigraine Mixtures," *STN HCA*, vol. 8 (1994), abstract—XP-002078672.
- Saadah, "Abortive Migraine Therapy with Oral Naproxen Sodium Plus Metoclopramide Plus Ergotamine Tartrate with Caffeine," *Headache* 32:95-97 (1992).
- Schuller, et al., "Recurrent Headaches: What Every Allergist Should Know," *Ann. Allergy Asthma Immunol.* 76:219-230 (1996).
- Sharma, et al., "An Update on Eicosanoids and Inhibitors of Cyclooxygenase Enzyme Systems," *Indian J. Exper. Biol.* 35:1025-1031 (1997).
- Sheftell, et al., "Subcutaneous Sumatriptan in a Clinical Setting: The First 100 Consecutive Patients with Acute Migraine in a Tertiary Care Center," *Headache* 34:67-72 (1994).
- Silberstein, "Treatment of the Migraine Attack," *Curr. Opin. Neurol.* 7:258-263 (1994).
- Solomon, "Therapeutic Advances in Migraine," *J. Clin. Pharmacol.* 33:200-209 (1993).
- Thomson, "A Study to Compare Oral Sumatriptan with Oral Aspirin plus Oral Metoclopramide in the Acute Treatment of Migraine," *Eur. Neurol.* 32:177-184 (1992).
- Todd, et al., "Naproxen: A Reappraisal of Its Pharmacology, and Therapeutic Use in Rheumatic Diseases and Pain States," *Drugs* 40:91-137 (1990).
- Tokola, et al., "Effects of Migraine Attack and Metoclopramide on the Absorption of Tolfenamic Acid," *Br. J. Clin. Pharmacol.* 17:67-75 (1984).
- Tokola, et al., "Tolfenamic Acid, Metoclopramide, Caffeine and their Combinations in the Treatment of Migraine Attacks," *Cephalalgia* 4:253-263 (1984).
- Von Seggern, et al., "Cost Considerations in Headache Treatment Part 2: Acute Migraine Treatment," *Headache* 36:493-502 (1996).
- Welch, "Drug Therapy of Migraine," *N. E. J. Med.* 329:1476-1483 (1993).

- Wilkinson, et al., "Migraine Cluster Headache—their Management with Sumatriptan: A Critical Review of the Current Clinical Experience," *Cephalalgia* 15:337-357 (1995).
- Witting, "Renal Papillary Necrosis Following Emergency Department Treatment of Migraine," *J. Emer. Med.* 14:373-376 (1996).
- Abstracts of Talley, et al., O.D. Searle Celebrix Registry 169590-42-5, "Celebrix," SC58635, patients for migraine headache: 5,466,823 (Nov. 1995); 5,504,215 (Apr. 1996); 5,508,426 (Apr. 1996); 5,510,496 (Apr. 1996); 5,516,907 (May 1996); 5,521,207 (May 1996); 5,563,165 (Oct. 1996); 5,700,816 (Dec. 1997); 5,753,688 (May 1998); 5,760,068 (Jun. 1998); and 5,932,598 (Aug. 1999).
- English language abstract of WO 94/26270, Reference B1 above.
- English language abstract of DE 195 42 281, Reference B16 above.
- English language abstract of JP 8-208516, Reference B7 above.
- Buzzi, et al., "Evidence for 5-HT_{1B/1D} Receptors Mediating the Antimigraine Effect of Sumatriptan and Dihydroergotamine," *Cephalalgia* 11:165-168 (1991).
- Sternfeld, et al., "The Chemical Evolution of N,N-Dimethyl-2-[5-(1,2,4-Triazol-4-YL)-1H-Indol-3-YL]Ethylamine (L-741,604) and Analogues: Potent and Selective Agonists for 5-HT_{1D} Receptors," *Biorganic and Medicinal Chemistry Letters* 6(15):1825-1830 (1996).
- Extract from *The Pharmacological Basis of Therapeutics*, Goodman & Gilman, 9th Ed.
- The Merck Index*, 12th Ed., 1996: THER-12-13.
- The Merck Index*, 13th Ed., 2001:1480.
- Physicians' Desk Reference*,® 50th Ed., 1996, Imitrex® : 1106-1110.
- Physicians' Desk Reference*,® 50th Ed., 1996, Naproxen® :2110-2113.
- Search results obtained from the "Integrity" and "Pharmaprojects" databases, following a query for "ALX-1323."
- Test Report prepared by Opponent Almirall Prodesfarma SA.
- Opposition papers filed by Opponent Almirall Prodesfarma SA.
- Opposition papers filed by Opponent Merck & Co., Inc.
- English language translation for CS 277 525, Reference B1 above.
- Brandes, et al., "Superior Efficacy of Combination Therapy over Monotherapy: Results of a Fixed Single-Tablet Formulation of Sumatriptan RT Technology and Naproxen Sodium in the Acute Treatment of Migraine in the Traditional Treatment Paradigm," Abstract (accepted for presentation), 48th Annual Specific Meeting of the American Headache Society, Jun. 22-26, Los Angeles, CA.
- Brandes, et al. "Therapeutic Clinical Benefits of a New Single-Tablet Formulation of Sumatriptan Formulated with RT Technology™ and Naproxen Sodium," *Cephalalgia* 25:860 (2005).
- Dahlöf, "Infrequent or Non-Response to Oral Sumatriptan Does Not Predict Response to Other Triptans—Review of Four Trials," *Cephalalgia* 26:98-106 (2005).
- Ferrari, et al., "Triptans (serotonin, 5-HT_{1B/1D} Agonists) in Migraine: Detailed Results and Methods of a Meta-Analysis of 53 Trials," *Cephalalgia* 22:633-658 (2002).
- Fowler, et al., "The Effect of Anti-Prostaglandins and Anti-Histamines on the Tolerability Profile of Sumatriptan," *New Adv. Headache Res.* 4:318 (1994).
- Fuseau, et al., "Effect of Encapsulation on Absorption of Sumatriptan Tablets: Data from Healthy Volunteers and Patients During a Migraine," *Clin. Therapeutics* 23:242-251 (2001).
- Krymchantowski, et al., "Rizatriptan Versus Rizatriptan Plus Rofecoxib Versus Rizatriptan Plus Tolfenamic Acid in the Acute Treatment of Migraine," *BMC Neurology* 4:10 (2004).
- Krymchantowski, "Naproxen Sodium Decreases Migraine Recurrence When Administered with Sumatriptan," *Arq Neuropsiquiatr* 58(2-B):428-430 (2000).
- Krymchantowski, et al., "Rizatriptan Combined with Rofecoxib vs. Rizatriptan for the Acute Treatment of Migraine: An Open Label Pilot Study," *Cephalalgia* 22:309-312 (2002).
- Louis, et al., "Crossover and Self-Controlled Designs in Clinical Research," *N. Engl. J. Med.* 310:24-31 (1984).
- Mandema, et al., "Therapeutic Benefit of Eletriptan Compared to Sumatriptan for the Acute Relief of a Migraine Pain—Results of a Model-Based Meta-Analysis that Accounts for Encapsulation," *Cephalalgia* 25:715-725 (2005).
- Silberstein, et al., "Superior Clinical Benefits of a New Single-Tablet Formulation of Sumatriptan Formulated with RT Technology and Naproxen Sodium," Abstract S35.001, 58th Annual Meeting of the American Academy of Neurology, presented Apr. 5, 2006, San Diego, CA.
- Smith, et al., "Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine," *Headache* 45:983-991 (2005).
- Spierings, "Eletriptan in Acute Migraine: A Double-Blind, Placebo-Controlled Comparison to Sumatriptan," *Neurology* 55:735-742 (2000).
- Visser, et al., "Risk Factors for Headache Recurrence after Sumatriptan: A Study in 366 Migraine Patients," *Cephalalgia* 16:264-269 (1996).
- Various Letters to the Editor, *Headache* 921-929 (Sep. 2003).
- Extract from *The Pharmacological Basis of Therapeutics*, Goodman & Gilman, 9th Ed., pp. 231 and 491-498.
- Response filed in European Oppositions of Merck and Almirall.
- Comparison of Chemical Structures of Ergots and Triptans, *Modern Drug Discovery*, vol. 2 (1999).
- European Search Report for Application Number EP03808537.9.


* cited by examiner

Figure 1.**Representative drawings of three different dosage form configurations.**


Panel A: Multi-Layer Tablet (Bilayer Tablet Shown)



Panel B: Naproxen Sodium Core Tablet with Sumatriptan Succinate in the Film-Coat



Panel C: Physical Admixture



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.